Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2008 | 12-2007 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -36,415 | -13,587 | -15,133 | 277 |
| Depreciation Amortization | 814 | 655 | 484 | N/A |
| Accounts receivable | -2,196 | -3,632 | -961 | N/A |
| Accounts payable and accrued liabilities | -61 | 564 | 56 | 25 |
| Other Working Capital | 1,593 | 181 | 447 | 277 |
| Other Operating Activity | 23,066 | 2,182 | 1,578 | -25 |
| Operating Cash Flow | $-13,199 | $-13,637 | $-13,530 | $554 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | 8,963 | -12,055 | N/A | N/A |
| PPE Investments | -509 | -882 | -787 | N/A |
| Net Acquisitions | -11,556 | N/A | N/A | N/A |
| Other Investing Activity | -7,000 | 0 | 0 | -68,636 |
| Investing Cash Flow | $-10,102 | $-12,937 | $-787 | $-68,636 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | N/A | N/A | 11,768 | 250 |
| Debt Issued | N/A | 9,905 | N/A | N/A |
| Debt Repayment | -4,000 | -1,193 | N/A | N/A |
| Common Stock Issued | 12,660 | 0 | 246 | 75,225 |
| Other Financing Activity | -6,250 | 53,215 | -588 | -5,995 |
| Financing Cash Flow | $2,410 | $61,927 | $11,426 | $69,480 |
| Exchange Rate Effect | 60 | 117 | 64 | N/A |
| Beginning Cash Position | 40,583 | 5,112 | 7,938 | N/A |
| End Cash Position | 19,752 | 40,583 | 5,112 | 1,398 |
| Net Cash Flow | $-20,830 | $35,470 | $-2,826 | $1,398 |
| Free Cash Flow | ||||
| Operating Cash Flow | -13,199 | -13,637 | -13,530 | 554 |
| Capital Expenditure | -509 | -882 | -787 | N/A |
| Free Cash Flow | -13,708 | -14,519 | -14,317 | 554 |